Next report date
Report period
Q1 2024
EPS estimate
0.04CHF
Revenue estimate
187.99 MCHF
−0.318CHF
−51.60 MCHF
611.61 MCHF
163.89 M
About ACADIA Pharmaceuticals Inc.
Sector
CEO
Stephen R. Davis
Headquarters
San Diego
Website
Employees (FY)
598
Founded
1993
FIGI
BBG00LVD4F39
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of DR6 is 15.232 CHF — it has decreased by 31.33% in the past 24 hours. Watch ACADIA PHARMACEUT stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange ACADIA PHARMACEUT stocks are traded under the ticker DR6.
ACADIA PHARMACEUT is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
DR6 stock is 45.63% volatile and has beta coefficient of 1.71. Track ACADIA PHARMACEUT stock price on the chart and check out the list of the most volatile stocks — is ACADIA PHARMACEUT there?
DR6 earnings for the last quarter are −0.37 CHF per share, whereas the estimation was −0.41 CHF resulting in a 10.65% surprise. The estimated earnings for the next quarter are 0.24 CHF per share. See more details about ACADIA PHARMACEUT earnings.
ACADIA PHARMACEUT revenue for the last quarter amounts to 193.81 M CHF despite the estimated figure of 176.07 M CHF. In the next quarter revenue is expected to reach 188.42 M CHF.
Yes, you can track ACADIA PHARMACEUT financials in yearly and quarterly reports right on TradingView.
DR6 stock has fallen by 31.33% compared to the previous week, the month change is a 31.33% fall, over the last year ACADIA PHARMACEUT has showed a 40.45% decrease.
DR6 net income for the last quarter is 38.56 M CHF, while the quarter before that showed −59.67 M CHF of net income which accounts for 164.62% change. Track more ACADIA PHARMACEUT financial stats to get the full picture.
Today ACADIA PHARMACEUT has the market capitalization of 2.57 B, it has decreased by 2.48% over the last week.
No, DR6 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, DR6 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ACADIA PHARMACEUT stock right from TradingView charts — choose your broker and connect to your account.
As of May 5, 2024, the company has 598.00 employees. See our rating of the largest employees — is ACADIA PHARMACEUT on this list?
We've gathered analysts' opinions on ACADIA PHARMACEUT future price: according to them, DR6 price has a max estimate of 35.56 CHF and a min estimate of 11.85 CHF. Watch DR6 chart and read a more detailed ACADIA PHARMACEUT stock forecast: see what analysts think of ACADIA PHARMACEUT and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ACADIA PHARMACEUT EBITDA is −57.08 M CHF, and current EBITDA margin is −9.34%. See more stats in ACADIA PHARMACEUT financial statements.